NEW YORK (GenomeWeb News) – Selventa today announced a scientific partnership with Rosa aimed at new drug discovery and development.
Financial and other terms of the deal were not disclosed.
In a statement, Cambridge, Mass.-based Selventa, formerly called Genstruct, said that the alliance provides "access to a synergistic combination of knowledge assets, proprietary data, physiologic model libraries, and expertise in disease areas such as oncology, immunology, respiratory, inflammatory, and metabolic diseases."
The two firms' combined modeling and analysis will integrate genomic, transcriptomic, in vitro, animal, and clinical data in a quantitative model.
Rosa provides drug-disease modeling and simulation services and has offices in Silicon Valley, Philadelphia, Seattle, and Europe.